Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Tonogold Posts Presentation Detailing the JAG Minerals Acquisition3.10.2024 09:00:00 CEST | Press release
Highlights TONOGOLD highlights the historic, low risk districts of uranium and vanadium production close to existing mineral production and processing. The Company will seek to accelerate the exploration, development and production of these critically important minerals. WOODLAND HILLS, CA / ACCESSWIRE / October 3, 2024 / TONOGOLD Resources Inc. (OTC PINK:TNGL) ("TONOGOLD" or the "Company") is pleased to inform shareholders that it has posted a presentation on its website detailing the previously announced acquisition of JAG Minerals Pty Ltd. This acquisition is the culmination of 12 months of work by both the TONOGOLD and JAG teams and, TONOGOLD believes, will lead to a leader in the uranium industry. The presentation can be accessed via this link: https://tonogold.com/corporate/presentation/ TONOGOLD CEO William Hunter stated: "We're pleased to be moving this transaction forward and look forward to operating these assets upon closing. The strategic importance of nuclear power in an i
New Preservica Application Drives Greater Efficiency and Transparency for UK Local Government Records3.10.2024 04:00:00 CEST | Press release
OXFORD, UK / ACCESSWIRE / October 3, 2024 / Preservica, a recognized leader in Active Digital Preservation™, has launched a new edition of its popular archiving software that's purpose-designed to enable UK Local Authority record-keeping teams to more efficiently maintain reliable, complete and retrievable long-term and permanent digital records in alignment with their obligations under the UK Public Records Act, Freedom of Information Act (FOIA) and UK GDPR (General Data Protection Regulation). Speed, automation and more efficient services Developed in collaboration with its community of nearly 50 UK local authority Records Offices and Archives, the new Preservica UK Local Government edition comes ready-configured with folders, metadata and workflows to enable record-keeping teams to rapidly create a trusted repository for managing and protecting many different types of long-term government records and digital formats including: Democratic Services - Councils and Committees Adult & Ch
Sama CEO Wendy Gonzalez to Speak at CogX Leadership Summit on AI3.10.2024 03:00:00 CEST | Press release
Gonzalez to discuss how to deploy responsible AI across an organization, and the importance of diverse leadership in fostering AI innovation and improving bottom line performance LONDON, UNITED KINGDOM / ACCESSWIRE / October 3, 2024 / Sama, the leader in purpose-built, responsible enterprise AI with agile data labeling for model development and supervised fine-tuning, today announced that CEO Wendy Gonzalez will speak in two separate sessions at the upcoming CogX Leadership Summit on AI, taking place in London on October 7, 2024. In her first session of the conference, slated for 12 noon in the Prince of Wales room, Gonzalez will join Gopal Ramchurn of Responsible AI UK and Nia Castelly, co-founder and head of legal at Checks, Google's AI-powered platform that helps developers build safer products by simplifying privacy compliance. Entitled Demystifying Responsible AI: A Guide for Leaders, this panel will explore the challenges, opportunities, regulatory considerations and strategies n
FINOS Releases First Draft of AI Governance Framework for Financial Institutions at OSFF NY with a Groundswell of Support from Industry Leaders1.10.2024 10:30:00 CEST | Press release
New FINOS Platinum Members include NVIDIA and Protect AI with Moody's joining as a Gold Member, alongside key financial services and AI industry leaders. NEW YORK, NY / ACCESSWIRE / October 1, 2024 / The Fintech Open Source Foundation (FINOS), the financial services umbrella of the Linux Foundation, proudly announced multiple Artificial Intelligence (AI) milestones at this week's Open Source in Finance Forum New York (OSFF NY). These developments include the draft release of a groundbreaking AI Governance Framework for financial institutions from the FINOS AI Readiness Special Interest Group (SIG) and an invitation to the broader community to participate in this now fully open initiative. Additionally, the broader FINOS AI initiative has been embraced by an impressive list of financial services and technology organizations and is attracting new members who are leaders in AI, including NVIDIA, Protect AI, and Moody's. "It's exciting to see how the FINOS membership has come together in a
Graid Technology Inc. and KLC Group Forge Groundbreaking Partnership to Redefine High-Speed RAID and Data-at-Rest Security1.10.2024 10:00:00 CEST | Press release
Protecting enterprise and military servers with unmatched NVMe RAID performance and the most advanced cybersecurity encryption on the market. SANTA CLARA, CA / ACCESSWIRE / October 1, 2024 / As data demands surge in today's hyper-competitive landscape, organizations are constantly seeking solutions that balance cutting-edge security with uncompromised performance. A new strategic partnership between Graid Technology, creators of SupremeRAID™, and KLC Group, innovators behind CipherDriveOne Plus, is set to redefine this balance with a first-of-its-kind solution for high-speed storage and NSA CSfC-certified Data-at-Rest (DAR) Security. Graid Technology Inc. and KLC Group Secure Groundbreaking Partnership to Disrupt High-Speed RAID and Data-at-Rest Security At the core of this collaboration is a novel approach to data security. Combining the National Security Agency's (NSA) Commercial Solutions for Classified (CSfC) Data-at-Rest (DAR) Security guidelines, the joint solution integrates enc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom